We perform rapid in vitro testing of drug efficacy against broad panels of cell lines to help identify responsive indications and subpopulations.
Study design and cell line selection can be the most critical part of understanding response to a particular drug.
Our catalog features more than 300 qualified cell lines covering dozens of tumor types, histologies and mutational statuses. Use our cell line selector to identify the best lines for your study.
Additionally, our cell biologists work with you to select panels of cell lines with known resistance/sensitivity profiles and moelcular characteristics–to formulate the study design that will be best suited to answer the hypothesis being tested.
While looking at one treatment condition is useful, the ability to look at combination treatments can be even more informative. In a cell line model, determining concentrations of each combination treatment can be burdensome. Our experienced team relies on established single agent IC50s, pharmacologic dose information, and known additive or synergistic effects to inform study design and drug concentration selection.
In order to measure drug response, we look at several endpoints, including:
- PD markers
We routinely report back growth inhibition curves and IC50 values across panels of cell lines for a given drug or drug combination treatment (Figure 1). To get the best understanding of drug sensitivity, our data analysis group; however, incorporates multiple cellular endpoints, as well as know molecular features for each cell line.
Figure 1. Drug treatment with vinorelbine, irinotecan and cisplatin against a panel of cell lines, including prostate (PC-3), lung (A549), colon (COLO-205), ovarian (OVCAR), leukocytic (HL-60) and breast (MCF-7).